Search company, investor...
Atomwise company logo


Founded Year



Grant | Alive

Total Raised


Last Raised

$2.3M | 2 yrs ago

About Atomwise

Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.

Headquarters Location

717 Market Street Suite 800

San Francisco, California, 94103,

United States


Missing: Atomwise's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

ESPs containing Atomwise

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Life Sciences / Biopharma Tech

AI drug discovery vendors are analyzing data (e.g., clinical trials data, EHRs, omics data, cellular images, and more) to develop novel drugs.

Atomwise named as Leader among 8 other companies, including Insilico Medicine, Cyclica, and Healx.

Missing: Atomwise's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Atomwise

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Atomwise is included in 6 Expert Collections, including AI 100.


AI 100

200 items


Artificial Intelligence

10,449 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry


Digital Health

12,654 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Biopharma Tech

838 items


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Atomwise Patents

Atomwise has filed 7 patents.

The 3 most popular patent topics include:

  • Classification algorithms
  • Machine learning
  • Statistical classification
patents chart

Application Date

Grant Date


Related Topics




Artificial neural networks, Machine learning, Classification algorithms, Spatial data analysis, Statistical classification


Application Date


Grant Date



Related Topics

Artificial neural networks, Machine learning, Classification algorithms, Spatial data analysis, Statistical classification



Latest Atomwise News

Drug Repurposing Market to witness CAGR outstanding 3.4% CAGR from 2023 to 2032

Jan 30, 2023

Drug Repurposing Market to witness CAGR outstanding 3.4% CAGR from 2023 to 2032 The size of the global market for Drug Repurposing was projected to be US$ 25.2 billion in 2021 and is anticipated to increase at a CAGR of 3.4% from 2023 to 2032. Drug repurposing, also known as drug reprofiling, helps businesses to identify fresh clinical uses for already-available medications. All licensed, archived, and experimental medications can be used in new ways. Access the sample report: The key players of the Global Drug Repurposing Market are: Astellas Pharma, Sanofi, GSK, Exscientia Limited, Atomwise Inc, Biovista Inc, Centene Corp (Health Net, LLC), NuMedii Inc, SOM Innovation Biotech S.A., Pfizer Inc, Recursion Pharmaceuticals Inc, Healx, Johnson & Johnson, Sosei Group Corp (SoseiHeptares), plc, and others include important participants in the drug repurposing market. Why drug repurposing is beneficial for pharmaceutical companies? Pharmaceutical companies have a sizable stockpile of abandoned, unsuccessful, and terminated medications. This serves as a collection of exclusive substances that can be regarded as intellectual property. By using them to treat new diseases, a lot of these candidate molecules can be conserved. Additionally, pharmaceutical firms have access to a sizable amount of information from studies on medication combinations and clinical studies. This information can be used to monitor the indications and targets that their current pharmacological portfolio is most effective at treating. Such medication recovery and conversion techniques offer the pharmaceutical industry a fantastic chance to optimize its portfolio by profitably reviving lost or abandoned medicinal ventures. Global drug repurposing market is expanding: Drugs that have been repurposed may allow the pharmaceutical industry to expand its current drug discovery business. Enhanced life cycles and patent administration for older pharmaceuticals are also made possible by drug repurposing. The duration of the medication development process is shortened for reused ingredients because the physicochemical and production procedures are already well-established. Read more about the report inclusions: The strongest prospects for drug repurposing are medications that have already passed pre-clinical and clinical testing for use in different disorders. Such medications will at the very least require simple efficacy tests and research on how they interact with diseases. Similar to this, many pre-clinical tests, bio-safety evaluations, and phase 1 clinical studies can be skipped for medicines that are already licensed and on the market in the event that new targets are found. If it is discovered that the majority of the medications that have been shelved or terminated are effective versus unidentified targets, their current interaction data, molecular characterization, and manufacturing techniques can be applied again. Although they will ultimately need to comply with all regulations, the R&D parts will be hassle-free. To find repurposed pharmaceuticals, both business and governmental drug development organizations can apply systematic, data-driven methodologies and computational biology/bioinformatics. A number of effective instances, including aspirin, sildenafil, and minoxidil, have demonstrated the effectiveness of drug repurposing. Benefits of drug repurposing: Drug repurposing is a powerful tool for finding treatments for undiagnosed or understudied diseases. For such disorders or disorders, whose pathophysiology is occasionally poorly defined, computational approaches for predictive repurposing offer a quick way to uncover probable alternatives. It may be possible to swiftly repurpose drugs that target the related protein or pathways using a large-scale genome-sequencing method to identify the genetic changes causing the condition. Therefore, repurposing such medications may be transferred directly into quick clinical trials even without engaging in wet-lab experiments, all without the need for preliminary research. Some recently discovered bioactive substances might not tolerate high plasma concentrations or have poor potencies. Existing drugs can operate better or promote tolerance when combined in synergistic ways. Such drug repurposing procedures can also be used in conjunction with cancer chemotherapies. Contrary to monotherapies, combination medication treatments offer one of the broadest research opportunities for drug repurposing. In the case of combinatorial treatments, the likelihood of discovering a potential application for an existing medicine increases dramatically. Therefore, the most logical and straightforward strategy in this field is to completely replace medications used in monotherapy or co-treatment with repurposed drugs. Due to the prominence of combination medications in medical therapy in recent years, this method has demonstrated significant potential. Drug repurposing can be effectively investigated for spectrum diseases that call for a patient-specific treatment regimen. Expanded combinatorial techniques will be necessary for clinical uses tailored to specific variances in the genome, transcription, proteomics, and metabolic activity, which can be made possible through drug repurposing. Global Drug Repurposing Market Key Segments: By Types Regulations and restriction on drug development can enable better outcomes for drug repurposing market: Legal restrictions on drug repurposing can hinder scientific advancements. There are a number of challenges involved in patent protection a novel use for an already-patentable medicine. Before conducting repurposing research, consent from the holders of any pending patents will be needed; even if a new candidate is proven to be effective, there may be issues with patent sharing or royalties. As a result, third parties have less incentive to repurpose drugs for illicit purposes. Proceed to purchase: Existing medications have a wide range of specialist literature or possible uses that are widely understood. Many medications are often used off-label or unregistered in clinical settings. The originality and design patents of repurposed medications may potentially be impacted by this. To efficiently combine huge amounts of data, functional and structural investigations, clinical trial paperwork, and tools based on genomics and proteomics, technological breakthroughs are needed in many different domains. Humans won’t be able to successfully track pharmacological action for unidentified targets unless all of these areas are coherent. Major diseases can be tackled through use of repurposed drugs: The method of drug repurposing can also help treat uncommon or undertreated conditions and diseases. By using repurposed medications, appealing incentives for various ailments can be created in an area with poor economic prospects. Although some health domains might not be economically beneficial, other types of value, such as a company’s social responsibility could be attained by such efforts. Pharmaceutical research for such uncommon or neglected diseases is made possible by taxpayer subsidies, tax exemptions, regulatory fee exemptions, and fast-track approval. By reusing currently available medications without spending money on R&D, drug repurposing can assist the pharmaceutical industry in overcoming financial barriers. Drug repurposing strategies can address drug administration simplicity. It is possible to create therapies or choose combination bioactive chemical therapies from already available medications. Repurposed drugs that are simple to give, take less time to treat people, and protect against the emergence of the resistant causal organism can take the role of effective but complex medicines. Related reports: Global Bronchoscope Market: insightSLICE  is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at . Contact us:

Atomwise Frequently Asked Questions (FAQ)

  • When was Atomwise founded?

    Atomwise was founded in 2012.

  • Where is Atomwise's headquarters?

    Atomwise's headquarters is located at 717 Market Street, San Francisco.

  • What is Atomwise's latest funding round?

    Atomwise's latest funding round is Grant.

  • How much did Atomwise raise?

    Atomwise raised a total of $176.42M.

  • Who are the investors of Atomwise?

    Investors of Atomwise include Bill & Melinda Gates Foundation, Y Combinator, DCVC, Tencent Holdings, Dolby Family Ventures and 12 more.

  • Who are Atomwise's competitors?

    Competitors of Atomwise include BERG, Cyclica, nference, Brightseed, BenevolentAI, Terray Therapeutics, Valence, Redesign Science, Exscientia, SyntheticGestalt and 21 more.

Compare Atomwise to Competitors

insitro Logo

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.

Cyclica Logo

Cyclica offers artificial intelligence (AI) and computational biophysics based drug discovery process. Its structure-based and artificial intelligence (AI) augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights. The company was founded in 2013 and is based in Toronto, Canada.

Aitia Logo

Aitia is a health tech company using Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology, neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’sDisease, with several more in development. Aitia’s partners include pharmaceutical companies, academic research and medical centers, medical societies, multi-omic data companies, and patient advocacy groups globally. Aitia was formerly GNS Healthcare and rebranded in January 2023. Aitia was founded in 2000 and is based in Somerville, Massachusetts.

Standigm Logo

Standigm is an AI and systems biology-based startup that aims to expedite the drug discovery process. Standigm develops a computer modeling technology that learns medical and biological information and predicts the action mechanism of pharmaceutics in advance. This technology can improve the pharmaceutical development process by tailoring the application of previous know-hows, come up with possible combinations of pharmaceuticals, and optimize the selection of candidates and participants for clinical trials.

Healx Logo

Healx provides drug discovery services. The company manufactures drugs using technology to bring treatments for rare diseases to patients. Its platform, Healnet, helps face challenges by analyzing drug and disease data points. The company was founded in 2014 and is based in Cambridge, U.K.

Aria Pharmaceuticals Logo
Aria Pharmaceuticals

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that discovers and develops novel small molecule therapies for complex and hard-to-treat diseases

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.